PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was notified by The Nasdaq Listing Qualifications Staff (“Nasdaq”) that the Company has regained compliance with the exchange’s continued listing standard for minimum share price under Rule 5550(a)(2) (the “Bid Price Rule”).
Related Questions
Will the reinstatement of Nasdaq compliance trigger a short‑cover rally or increased buying pressure on CGTX?
Is there a risk that the company's bid price could fall below the $1 threshold again, prompting another delisting warning?
How might the regained compliance affect the stock's eligibility for inclusion in index funds and its overall liquidity?